ethyl 3-(3-chloro-2-fluorophenyl)-3-oxopropanoate | 1240912-95-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 3-(3-chloro-2-fluorophenyl)-3-oxopropanoate
• CAS: 1240912-95-1
• 化学式: C₁₁H₁₀ClFO₃
• 分子量: 244.65
• InChiKey: KBGGGJWULKQLNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(3-chloro-2-fluorophenyl)-3-oxopropanoate 在 4-乙酰氨基苯磺酰叠氮 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 ethyl 3-(3-chloro-2-fluorophenyl)-2-diazo-3-oxopropanoate
  参考文献：
  名称：

  [EN] PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE PYRAZOLO[4,3-C]CINNOLIN-3-ONE

  摘要：

  本发明涉及式(I)的吡唑并[4,3-c]咖啉-3-酮化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。

  公开号：

  WO2010096338A1

文献信息

• PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20110301167A1

  公开（公告）日：2011-12-08

  The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]茚啉-3-酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体介导的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病的方法。
• Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators
  申请人：Beshore Douglas C.

  公开号：US08653079B2

  公开（公告）日：2014-02-18

  The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]茚啉-3-酮化合物，其为M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的方法。
• Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
  申请人：Beshore Douglas C.

  公开号：US08486946B2

  公开（公告）日：2013-07-16

  The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]茚啉-3-酮化合物，它们是M1受体正向变构调节剂，并且在治疗与M1受体有关的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含这些化合物的制药组合物以及在治疗M1受体介导的疾病方面使用这些化合物和组合物。
• PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20130102599A1

  公开（公告）日：2013-04-25

  The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]茚啉-3-酮化合物，其为M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的方法。
• [EN] LIVER-SPECIFIC AMPK AGONIST, PREPARATION METHOD THEREFOR AND USES THEREOF<br/>[FR] AGONISTE DE L'AMPK SPÉCIFIQUE AU FOIE, SON PROCÉDÉ DE PRÉPARATION ET SES APPLICATIONS<br/>[ZH] 肝脏特异性AMPK激动剂及其制法和应用
  申请人：CASCADE SHANGHAI PHARMACEUTICAL TECH CO LTD

  公开号：WO2020143800A1

  公开（公告）日：2020-07-16

  本发明提供了肝脏特异性AMPK激动剂及其制法和应用。具体地，本发明提供了一种如下式(I)所示的化合物，以及其用于治疗包含非酒精性脂肪肝(NAFL)、非酒精性脂肪肝炎(NASH)及其相关肝硬化、肝癌在内的非酒精性脂肪肝病(NAFLD)，或肥胖、糖尿病、高甘油三酯血症、高胆固醇血症、动脉粥样硬化、心血管疾病、代谢性疾病等疾病的用途。其中，各基团定义如说明书中所示。